Stellate Multiform Amelanotic Choroidopathy (SMACH)

From EyeWiki

All content on Eyewiki is protected by copyright law and the Terms of Service. This content may not be reproduced, copied, or put into any artificial intelligence program, including large language and generative AI models, without permission from the Academy.


Disease

Stellate multiform amelanotic choroidopathy (SMACH) is a recently described choroidal pathology with unique multimodal imaging features.[1] Clinically, it is characterized by a multiform lesion, frequently associated with serous retinal detachment (in around 56%) noted on optical coherence tomography (OCT) and overlying retinal pigment epithelial (RPE) changes.[1] It was first reported by van Dijk and Boon in 2021 under the designation of “serous maculopathy due to aspecific choroidopathy” (SMACH).[2] Since then, a multicenter series of 18 patients, a Korean multicenter series of 8 patients, and several smaller series and case reports have been published.[1] [3][4] [5][6][7][8][9][10] As subretinal fluid was not present in some of these cases, Ramtohul et al. proposed a nomenclature change to “stellate multiform amelanotic choroidopathy”, to maintain its former abbreviation, SMACH.[1] SMACH is typically unilateral, although bilateral involvement has been reported.[11]

Etiology

The etiology of SMACH is unknown. A choroidal origin has been proposed, with early onset of disease and lesion size stability pointing to a congenital dysgenesis.[1] An atypical staphyloma found in some of the affected individuals suggests that choroidal flow turbulence could also play a role.[3]A presumed case of SMACH has been described in a patient with neurofibromatosis type 2-related schwannomatosis. Whether this reflects a true association or a coincidence is not known.[12]

Risk Factors

A retrospective review including 18 patients diagnosed with SMACH found that the majority were young individuals (mean age 28 ± 19 years), with a similar gender distribution (10 men and 8 women).[1]A Korean multicenter series of 8 patients found a similar mean age (30.5 ± 22.5 years; 3 males and 5 females).[13]The youngest reported patient was 5 years old,[14] and cases have also been described at 67 years and, as a presumed diagnosis, at 76 years.[15][16]The diagnosis should therefore not be excluded on the basis of age alone.

General Pathology

The lack of pathological data limits the current understanding of the etiology and pathophysiology of SMACH.[1]

Pathophysiology

It is theorized that subretinal fluid accumulation in SMACH results from choriocapillaris compression by the choroidal lesion, increasing hydrostatic pressure, and damage to the outer blood-retinal barrier.[1][2]

Diagnosis

SMACH is a clinical diagnosis suspected after fundoscopy and confirmed by characteristic findings in multimodal imaging evaluation, comprising near-infrared reflectance (NIR), optical coherence tomography (OCT), fundus autofluorescence (FAF), fluorescein and indocyanine green angiography (FA, ICGA) and OCT angiography.[1][2][3] A large study on SMACH included 'eyes with findings on multimodal imaging consistent with SMACH, defined as serous retinal detachment associated with pigmentary changes on ophthalmoscopy, disruption and elevation of the RPE by a thickened and structurally altered choroid on OCT, hypofluorescent and hyperfluorescent changes on FA (fluorescein angiogram), absence of focal choroidal hyperpermeability on indocyanine green angiography (ICGA), and absence of macular neovascularization (MNV) on OCT angiography (OCTA). Extramacular lesions or eyes without serous retinal detachment but showing a similar imaging pattern were also included.'[2][1] These criteria are not absolute. Focal hyperfluorescence on ICGA and bilateral involvement have since been described in otherwise typical cases.[17][18][19]

Symptoms

Affected individuals can be asymptomatic or complain of gradual vision loss or metamorphopsia.[1]

Signs

On ophthalmoscopic examination, SMACH appears as a typically unilateral, yellowish-orange, dendriform lesion. Radial, finger-like protrusions extending from the lesion in a stellate configuration are the distinguishing features of this diagnosis. Fine hypo/hyperpigmentation can be seen, corresponding to retinal pigment epithelium (RPE) changes. Most reported cases are located in the macula, but extrafoveal forms have also been described.[1][2] The images of a representative case can be accessed here.[3] The stellate pattern or dendritic protrusions from the lesion are better visible with en-face structural OCT, near-infrared reflectance, and early stage ICGA.[1] En face OCT usually reveals more finger-like projections compared to ophthalmoscopy.

Diagnostic procedures

Reported SMACH features on multimodal imaging include:[1][2][3]

  • NIR: A hyperreflective lesion layout is reproduced, highlighting the radial projections making up its stellate shape.
  • OCT: Cross-sectional OCT shows choroidal architecture disorganization with irregular hyperreflective thickening of the inner choroid ('hyperreflective fibrous-like changes').[1] Subretinal fluid, RPE elevation (anterior protrusion of RPE) and outer retinal disruption may be seen above the lesion, while choroidal stromal hyperreflectivity may be noted below. Normal outer choroidal (Haller) vessels and choroidoscleral junction may be noted.
  • FAF: Both normal, speckled hypoautofluorescence (from RPE alteration) and annular hyperautofluorescence (due to vitelliform lesion) patterns have been described.
  • FA: Granular hypo/hyperfluorescence (from RPE changes). A Korean series described a central core of angiomatous vessels with mild leakage, present with or without subretinal fluid.[20] Focal or multifocal leakage may also be seen.[21]
  • ICGA: Early and late hypofluorescent lesion layout, with characteristic finger-like projections. Focal choroidal hyperpermeability is usually absent. However, a late pinpoint focus of hyperfluorescence with faint staining, and focal leakage in the mid and late phases, have each been reported in single cases.[22][23]
  • En face OCT: Segmentation at the level of the inner choroid shows a hyperreflective lesion with finger-like projections in a stellate configuration.[1]
  • OCTA: Choriocapillaris flow is preserved, and there is no macular neovascularization.[1][24]

Differential diagnosis

SMACH may masquerade as other chorioretinal pathology, namely

  • central serous chorioretinopathy,
  • Best vitelliform macular dystrophy,
  • macular neovascularization (idiopathic in young patients, or neovascular age-related macular degeneration in older patients),[25][26]
  • pachychoroid spectrum diseases,[27]
  • placoid chorioretinitis, and
  • choroidal tumors [amelanotic choroidal nevus or melanoma, choroidal osteoma, choroidal metastasis, choroidal lymphoma, choroidal hemangioma, and focal scleral nodule (previously called solitary idiopathic choroiditis).][1][28] In published cases, the initial working diagnoses have included idiopathic macular neovascularization, chronic central serous chorioretinopathy, choroidal mass, uveal lymphoma, and an infectious process.[29][30][31][32]

Management

There is no consensus on the management of SMACH because few cases have been reported. Observation is appropriate in most patients, as the subretinal fluid may fluctuate or resolve spontaneously and vision usually remains stable.[1][33] [34]Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections have not been effective.[1][35][36] In the original multicenter series, photodynamic therapy (PDT) also gave no benefit.[1] More recently, complete resolution of subretinal fluid was reported after full-dose PDT (50 J/cm², 83 seconds) directed at an area of focal leakage on ICGA in an 18-year-old patient,[37] and a further report describes a favorable response to PDT in additional patients.[38] PDT may therefore be considered in selected eyes with persistent, symptomatic subretinal fluid and focal leakage on ICGA, although the evidence is limited to case reports. Correct recognition of SMACH is important mainly to avoid unnecessary treatment, such as repeated anti-VEGF injections or corticosteroids.[39][40]

Prognosis

The natural course of SMACH is punctuated by spontaneous fluctuation of the subretinal fluid, while the size of the choroidal lesion remained stationary (non-progressive nature). Vision loss may be related to subretinal fluid accumulation and/or outer retinal disruption. During the follow-up period of the retrospective review (mean duration 9 years), best corrected visual acuity remained relatively stable.[1]In a Korean series, best corrected visual acuity was 20/25 or better in 6 of 8 patients, and reduced vision in the other two was attributed to cataract. Subretinal fluid, present in 3 of 8 eyes, resolved almost completely with or without treatment.[41]

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 Ramtohul P, Pellegrini M, Pichi F, et al. STELLATE MULTIFORM AMELANOTIC CHOROIDOPATHY: Clinical and Multimodal Imaging Features. Retina. 2023;43(9):1448-1461. doi:10.1097/IAE.0000000000003826
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 van Dijk EHC, Boon CJF. Serous business: Delineating the broad spectrum of diseases with subretinal fluid in the macula. Prog Retin Eye Res. 2021;84:100955. doi:10.1016/j.preteyeres.2021.100955
  3. ↑ 3.0 3.1 3.2 3.3 3.4 van Dijk EHC, Ossewaarde-van Norel J, Vingerling JR, Cohen SY, Boon CJF. Serous Maculopathy Due to Aspecific Choroidopathy (SMACH). Asia Pac J Ophthalmol (Phila). 2023;12(5):496-498. doi:10.1097/APO.0000000000000550
  4. ↑ Carrera W, Liang MC. A 19-year-old asymptomatic woman. Retin Cases Brief Rep. 2025. doi:10.1097/ICB.0000000000001716
  5. ↑ van Gorcom L, Ikinci M, Amarakoon S. Successful treatment of stellate multiform amelanotic choroidopathy with photodynamic therapy: A case report. Am J Ophthalmol Case Rep. 2025;39:102410. doi:10.1016/j.ajoc.2025.102410
  6. ↑ Ucan Gunduz G, Onal Gunay B, Doganay S, Yalcinbayir O, Gelisken O. Multimodal and clinical findings of three cases with stellate multiform amelanotic choroidopathy. Eur J Ophthalmol. 36(5):NP8-NP14. doi:10.1177/11206721251397688
  7. ↑ Ucan Gunduz G, Onal Gunay B, Doganay S, Yalcinbayir O, Gelisken O. Multimodal and clinical findings of three cases with stellate multiform amelanotic choroidopathy. Eur J Ophthalmol. 36(5):NP8-NP14. doi:10.1177/11206721251397688
  8. ↑ Gracia-Rovira E, Miralles Pechuán V, Hernandez Pérez D, et al. Stellate Multiform Amelanotic Choroidopaty and the importance of its diagnosis to avoid overtreatment. Arch Soc Esp Oftalmol (Engl Ed). 101(1):502451. doi:10.1016/j.oftale.2025.502451
  9. ↑ Jeon J, Kwak JJ, Seoung HJ, et al. Clinical and imaging features of SMACH. BMC Ophthalmol. 2026;26(1):281. doi:10.1186/s12886-026-04810-z
  10. ↑ Arango-Hurtado M, Quintero-Lizcano K, Díaz-Vargas JA, Mejía ST, Velásquez SR. SMACH: A Rare, Non-Progressive Retinal Disorder - Key Insights into Its Clinical and Imaging Characteristics. A Case Report. Rom J Ophthalmol. 2026;70(2):326-329. doi:10.22336/rjo.2026.44
  11. ↑ Bechara Ghobril A, Medina RJ, Shields CL. Bilateral Stellate Multiform Amelanotic Choroidopathy in a Young Female Patient. JAMA Ophthalmol. 2026. doi:10.1001/jamaophthalmol.2026.5075
  12. ↑ Wang J, Li F, Ran Z. Presumed Stellate Multiform Amelanotic Choroidopathy (SMACH) in Neurofibromatosis type 2-related schwannomatosis. Retin Cases Brief Rep. 2026. doi:10.1097/ICB.0000000000001992
  13. ↑ Jeon J, Kwak JJ, Seoung HJ, et al. Clinical and imaging features of SMACH. BMC Ophthalmol. 2026;26(1):281. doi:10.1186/s12886-026-04810-z
  14. ↑ Ucan Gunduz G, Onal Gunay B, Doganay S, Yalcinbayir O, Gelisken O. Multimodal and clinical findings of three cases with stellate multiform amelanotic choroidopathy. Eur J Ophthalmol. 36(5):NP8-NP14. doi:10.1177/11206721251397688
  15. ↑ Arango-Hurtado M, Quintero-Lizcano K, Díaz-Vargas JA, Mejía ST, Velásquez SR. SMACH: A Rare, Non-Progressive Retinal Disorder - Key Insights into Its Clinical and Imaging Characteristics. A Case Report. Rom J Ophthalmol. 2026;70(2):326-329. doi:10.22336/rjo.2026.44
  16. ↑ Ren X, Yu X, Huang S, Qi X, Wang S, Sun Y. Serous Maculopathy due to Aspecific Choroidopathy (SMACH): a case report with differential diagnosis based on multimodal imaging analysis. Doc Ophthalmol. 153(2):281-288. doi:10.1007/s10633-026-10120-y
  17. ↑ Carrera W, Liang MC. A 19-year-old asymptomatic woman. Retin Cases Brief Rep. 2025. doi:10.1097/ICB.0000000000001716
  18. ↑ van Gorcom L, Ikinci M, Amarakoon S. Successful treatment of stellate multiform amelanotic choroidopathy with photodynamic therapy: A case report. Am J Ophthalmol Case Rep. 2025;39:102410. doi:10.1016/j.ajoc.2025.102410
  19. ↑ Bechara Ghobril A, Medina RJ, Shields CL. Bilateral Stellate Multiform Amelanotic Choroidopathy in a Young Female Patient. JAMA Ophthalmol. 2026. doi:10.1001/jamaophthalmol.2026.5075
  20. ↑ Jeon J, Kwak JJ, Seoung HJ, et al. Clinical and imaging features of SMACH. BMC Ophthalmol. 2026;26(1):281. doi:10.1186/s12886-026-04810-z
  21. ↑ van Gorcom L, Ikinci M, Amarakoon S. Successful treatment of stellate multiform amelanotic choroidopathy with photodynamic therapy: A case report. Am J Ophthalmol Case Rep. 2025;39:102410. doi:10.1016/j.ajoc.2025.102410
  22. ↑ Carrera W, Liang MC. A 19-year-old asymptomatic woman. Retin Cases Brief Rep. 2025. doi:10.1097/ICB.0000000000001716
  23. ↑ van Gorcom L, Ikinci M, Amarakoon S. Successful treatment of stellate multiform amelanotic choroidopathy with photodynamic therapy: A case report. Am J Ophthalmol Case Rep. 2025;39:102410. doi:10.1016/j.ajoc.2025.102410
  24. ↑ van Gorcom L, Ikinci M, Amarakoon S. Successful treatment of stellate multiform amelanotic choroidopathy with photodynamic therapy: A case report. Am J Ophthalmol Case Rep. 2025;39:102410. doi:10.1016/j.ajoc.2025.102410
  25. ↑ van Gorcom L, Ikinci M, Amarakoon S. Successful treatment of stellate multiform amelanotic choroidopathy with photodynamic therapy: A case report. Am J Ophthalmol Case Rep. 2025;39:102410. doi:10.1016/j.ajoc.2025.102410
  26. ↑ Arango-Hurtado M, Quintero-Lizcano K, Díaz-Vargas JA, Mejía ST, Velásquez SR. SMACH: A Rare, Non-Progressive Retinal Disorder - Key Insights into Its Clinical and Imaging Characteristics. A Case Report. Rom J Ophthalmol. 2026;70(2):326-329. doi:10.22336/rjo.2026.44
  27. ↑ Arango-Hurtado M, Quintero-Lizcano K, Díaz-Vargas JA, Mejía ST, Velásquez SR. SMACH: A Rare, Non-Progressive Retinal Disorder - Key Insights into Its Clinical and Imaging Characteristics. A Case Report. Rom J Ophthalmol. 2026;70(2):326-329. doi:10.22336/rjo.2026.44 (PMID: 42572626
  28. ↑ Fung AT, Waldstein SM, Gal-Or O, et al. Focal Scleral Nodule: A New Name for Solitary Idiopathic Choroiditis and Unifocal Helioid Choroiditis. Ophthalmology. 2020;127(11):1567-1577. doi:10.1016/j.ophtha.2020.04.018
  29. ↑ van Gorcom L, Ikinci M, Amarakoon S. Successful treatment of stellate multiform amelanotic choroidopathy with photodynamic therapy: A case report. Am J Ophthalmol Case Rep. 2025;39:102410. doi:10.1016/j.ajoc.2025.102410
  30. ↑ Gracia-Rovira E, Miralles Pechuán V, Hernandez Pérez D, et al. Stellate Multiform Amelanotic Choroidopaty and the importance of its diagnosis to avoid overtreatment. Arch Soc Esp Oftalmol (Engl Ed). 101(1):502451. doi:10.1016/j.oftale.2025.502451
  31. ↑ Jeon J, Kwak JJ, Seoung HJ, et al. Clinical and imaging features of SMACH. BMC Ophthalmol. 2026;26(1):281. doi:10.1186/s12886-026-04810-z
  32. ↑ Bezci Aygün F, Özkorkmaz AC, Karaca B, Kıratlı H, Kadayıfçılar S. Stellate Multiform Amelanotic Choroidopathy: Two Cases Mimicking a Choroidal Mass and Chronic Central Serous Chorioretinopathy. Turk J Ophthalmol. 2026. doi:10.4274/tjo.galenos.2026.69449
  33. ↑ Ucan Gunduz G, Onal Gunay B, Doganay S, Yalcinbayir O, Gelisken O. Multimodal and clinical findings of three cases with stellate multiform amelanotic choroidopathy. Eur J Ophthalmol. 36(5):NP8-NP14. doi:10.1177/11206721251397688 (PMID: 41432686)
  34. ↑ Jeon J, Kwak JJ, Seoung HJ, et al. Clinical and imaging features of SMACH. BMC Ophthalmol. 2026;26(1):281. doi:10.1186/s12886-026-04810-z
  35. ↑ van Gorcom L, Ikinci M, Amarakoon S. Successful treatment of stellate multiform amelanotic choroidopathy with photodynamic therapy: A case report. Am J Ophthalmol Case Rep. 2025;39:102410. doi:10.1016/j.ajoc.2025.102410
  36. ↑ Ucan Gunduz G, Onal Gunay B, Doganay S, Yalcinbayir O, Gelisken O. Multimodal and clinical findings of three cases with stellate multiform amelanotic choroidopathy. Eur J Ophthalmol. 36(5):NP8-NP14. doi:10.1177/11206721251397688
  37. ↑ van Gorcom L, Ikinci M, Amarakoon S. Successful treatment of stellate multiform amelanotic choroidopathy with photodynamic therapy: A case report. Am J Ophthalmol Case Rep. 2025;39:102410. doi:10.1016/j.ajoc.2025.102410
  38. ↑ Su M, Zheng W, Hong N, et al. Favourable response to photodynamic therapy in patients with stellate multiform amelanotic choroidopathy. Eye (Lond). 2026. doi:10.1038/s41433-026-04960-w
  39. ↑ Ucan Gunduz G, Onal Gunay B, Doganay S, Yalcinbayir O, Gelisken O. Multimodal and clinical findings of three cases with stellate multiform amelanotic choroidopathy. Eur J Ophthalmol. 36(5):NP8-NP14. doi:10.1177/11206721251397688
  40. ↑ Gracia-Rovira E, Miralles Pechuán V, Hernandez Pérez D, et al. Stellate Multiform Amelanotic Choroidopaty and the importance of its diagnosis to avoid overtreatment. Arch Soc Esp Oftalmol (Engl Ed). 101(1):502451. doi:10.1016/j.oftale.2025.502451
  41. ↑ Jeon J, Kwak JJ, Seoung HJ, et al. Clinical and imaging features of SMACH. BMC Ophthalmol. 2026;26(1):281. doi:10.1186/s12886-026-04810-z